Astrazeneca Pharma India Ltd vs Par Drugs Chemicals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 17, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8488 as of 15 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 yearsThe P/E Ratio of Par Drugs & Chemicals Ltd changed from 6.6 on March 2021 to 7.8 on March 2025 . This represents a CAGR of 3.40% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 yearsThe Market Cap of Par Drugs & Chemicals Ltd changed from ₹ 76.17 crore on March 2021 to ₹ 104.5 crore on March 2025 . This represents a CAGR of 6.53% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 618.18 crore. This represent the decline of -100% The revenue of Par Drugs & Chemicals Ltd for the Mar '26 is ₹ 19.97 crore as compare to the Dec '25 revenue of ₹ 30.67 crore. This represent the decline of -34.89% The ebitda of Astrazeneca Pharma India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 51.44 crore. This represent the decline of -100% The ebitda of Par Drugs & Chemicals Ltd for the Mar '26 is ₹ 1.8 crore as compare to the Dec '25 ebitda of ₹ 7.39 crore. This represent the decline of -75.64% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Par Drugs & Chemicals Ltd changed from ₹ 2.53 crore to ₹ 0.85 crore over 8 quarters. This represents a CAGR of -42.04% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Par Drugs & Chemicals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Par Drugs & Chemicals Ltd

Par Drugs and Chemicals Limited was originally incorporated as a Private Limited Company with the name 'Par Drugs and Chemicals Private Limited' at Bhavnagar, Gujarat on 26 February 1999.
Subsequently, the Company was converted into a Public Limited Company and the name of the Company was changed to 'Par Drugs and Chemicals Limited' on 5 November 2018. The Company began in 1982 under the vision of the founder, Late Shri Vallabhbhai J. Savani.
The Company discontinued its existing pharmaceutical and chemical operations and diversified into an entirely new vertical line of business.
With shareholder approval, the Company is investing in real estate & construction, clean & renewable energy, and capital markets. At present, Company is engaged in manufacturing of Active Pharma Ingredients and fine chemicals (API) for domestic market as well as for exports to international markets.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Par Drugs & Chemicals Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Par Drugs & Chemicals Ltd?

Market cap of Astrazeneca Pharma India Ltd is 21,221 Cr while Market cap of Par Drugs & Chemicals Ltd is 107 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Par Drugs & Chemicals Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Par Drugs & Chemicals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Par Drugs & Chemicals Ltd?

As of May 17, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8488.45. On the other hand, Par Drugs & Chemicals Ltd stock price is INR ₹87.29.

How do dividend payouts of Astrazeneca Pharma India Ltd and Par Drugs & Chemicals Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Par Drugs & Chemicals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.